Understanding the mechanisms underlying Angelman syndrome and developing novel treatments – University of Copenhagen

DRA > Activities > 2019 > Symposier og lectures > Understanding the mech...

Understanding the mechanisms underlying Angelman syndrome and developing novel treatments

DRA lecture held by Professor Ype Elgersma, ERASMUS MC, Department of Neuroscience, Rotterdam, the Netherlands.

Dr. Elgersma’s lab seeks to get insight into the molecular mechanisms underlying the neurodevelopmental disorder Angelman syndrome. Central to the approach is the use of genetically engineered Ube3a mice as a tool to dissect these mechanisms at the biochemical, cellular (including electrophysiology) and behavioral level with the goal of providing insight into the molecular mechanisms in Angelman syndrome, particularly learning and memory.

Dr. Elgersma is founder (and director) of the ENCORE expertise center for neurodevelopmental disorders. ENCORE encompasses 6 nationally recognised expertise enters and participates in 2 European Reference Networks (ERNs). It includes (amongst others) the national referral center for TSC, Angelman Syndrome, Neurofibromatosis, Fragile X, and Genetic forms of Autism. Several clinical trials are currently ongoing in this center.


The lecture is organised on behalf of the graduate programme in pharmaceutical sciences, Drug Research Academy, by Associate Professor Petrine Wellendorph, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen.

The DRA lecture is free of charge and open for attendance by all interested parties. It is not necessary to pre-register.